434 related articles for article (PubMed ID: 9421741)
1. Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in vivo.
Jordan A; Scholz R; Wust P; Fähling H; Krause J; Wlodarczyk W; Sander B; Vogl T; Felix R
Int J Hyperthermia; 1997; 13(6):587-605. PubMed ID: 9421741
[TBL] [Abstract][Full Text] [Related]
2. Magnetic fluid hyperthermia (MFH)reduces prostate cancer growth in the orthotopic Dunning R3327 rat model.
Johannsen M; Thiesen B; Jordan A; Taymoorian K; Gneveckow U; Waldöfner N; Scholz R; Koch M; Lein M; Jung K; Loening SA
Prostate; 2005 Aug; 64(3):283-92. PubMed ID: 15726645
[TBL] [Abstract][Full Text] [Related]
3. Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
Murata R; Horsman MR
Int J Hyperthermia; 2004 Jun; 20(4):393-404. PubMed ID: 15204520
[TBL] [Abstract][Full Text] [Related]
4. Combined adriamycin and hyperthermia treatment of a murine mammary carcinoma in vivo.
Overgaard J
Cancer Res; 1976 Sep; 36(9 pt.1):3077-81. PubMed ID: 975075
[TBL] [Abstract][Full Text] [Related]
5. Cellular uptake of magnetic fluid particles and their effects on human adenocarcinoma cells exposed to AC magnetic fields in vitro.
Jordan A; Wust P; Scholz R; Tesche B; Fähling H; Mitrovics T; Vogl T; Cervós-Navarro J; Felix R
Int J Hyperthermia; 1996; 12(6):705-22. PubMed ID: 8950152
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle distribution and temperature elevations in prostatic tumours in mice during magnetic nanoparticle hyperthermia.
Attaluri A; Ma R; Qiu Y; Li W; Zhu L
Int J Hyperthermia; 2011; 27(5):491-502. PubMed ID: 21756046
[TBL] [Abstract][Full Text] [Related]
7. The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization.
Hokland SL; Horsman MR
Int J Hyperthermia; 2007 Nov; 23(7):599-606. PubMed ID: 18038290
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of local tumour control by misonidazole and hyperthermia.
Stone HB
Br J Cancer Suppl; 1978 Jun; 3():178-83. PubMed ID: 277222
[TBL] [Abstract][Full Text] [Related]
9. Study of non-uniform nanoparticle liposome extravasation in tumour.
Liu P; Zhang A; Xu Y; Xu LX
Int J Hyperthermia; 2005 May; 21(3):259-70. PubMed ID: 16019852
[TBL] [Abstract][Full Text] [Related]
10. Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo.
Horsman MR; Christensen KL; Overgaard J
Int J Hyperthermia; 1989; 5(2):123-36. PubMed ID: 2926180
[TBL] [Abstract][Full Text] [Related]
11. The usefulness of continuous administration of hypoxic cytotoxin combined with mild temperature hyperthermia, with reference to effects on quiescent tumour cell populations.
Masunaga S; Nagasawa H; Uto Y; Hori H; Suzuki M; Nagata K; Kinashi Y; Ono K
Int J Hyperthermia; 2005 Jun; 21(4):305-18. PubMed ID: 16019857
[TBL] [Abstract][Full Text] [Related]
12. Inhibition by whole-body hyperthermia with far-infrared rays of the growth of spontaneous mammary tumours in mice.
Udagawa Y; Nagasawa H; Kiyokawa S
Anticancer Res; 1999; 19(5B):4125-30. PubMed ID: 10628363
[TBL] [Abstract][Full Text] [Related]
13. Segmentation of dynamic contrast enhanced magnetic resonance imaging data.
Nielsen T; Mouridsen K; Maxwell RJ; Stødkilde-Jørgensen H; Østergaard L; Horsman MR
Acta Oncol; 2008; 47(7):1265-70. PubMed ID: 18661437
[TBL] [Abstract][Full Text] [Related]
14. Radiation administered as a large single dose or in a fractionated schedule: Role of the tumour vasculature as a target for influencing response.
Horsman MR; Nielsen T; Østergaard L; Overgaard J
Acta Oncol; 2006; 45(7):876-80. PubMed ID: 16982553
[TBL] [Abstract][Full Text] [Related]
15. Exposure of Sprague-Dawley rats to a 50-Hertz, 100-microTesla magnetic field for 27 weeks facilitates mammary tumorigenesis in the 7,12-dimethylbenz[a]-anthracene model of breast cancer.
Thun-Battersby S; Mevissen M; Löscher W
Cancer Res; 1999 Aug; 59(15):3627-33. PubMed ID: 10446973
[TBL] [Abstract][Full Text] [Related]
16. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
17. Histopathological changes in transplanted mouse mammary carcinoma following hyperthermia with or without radiation.
Jo S; Hiraoka M; Akuta K; Nishimura Y; Furuta M; Takahashi M; Abe M
Jpn J Cancer Res; 1986 Nov; 77(11):1095-101. PubMed ID: 3098719
[TBL] [Abstract][Full Text] [Related]
18. Antitumour effectiveness of hyperthermia is potentiated by local application of electric pulses to LPB tumours in mice.
Karner KB; Lesnicar H; Cemazar M; Sersa G
Anticancer Res; 2004; 24(4):2343-8. PubMed ID: 15330182
[TBL] [Abstract][Full Text] [Related]
19. NTP Toxicology and Carcinogenesis Studies of Pentachloroanisole (CAS No. 1825-21-4) in F344 Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Apr; 414():1-284. PubMed ID: 12616284
[TBL] [Abstract][Full Text] [Related]
20. Interaction of hyperthermia and cis-diamminedichloroplatinum(II) alone or combined with radiation in a C3H mammary carcinoma in vivo.
Overgaard J; Radacic MM; Grau C
Cancer Res; 1991 Jan; 51(2):707-11. PubMed ID: 1985787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
